Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
In the efficacy population (n=335), at median follow-up of 25·0 months, treatment with rucaparib was linked to improved median progression-free survival vs. chemotherapy (7.4 vs.5.7 months; HR 0.64; 95% CI 0.49–0.84; p=0.0010).
Source:
The Lancet Oncology
SPS commentary:
According to a commentary, these data show that rucaparib is active and a reasonable alternative to chemotherapy for women with advanced, pretreated, BRCA1/2-mutated ovarian cancer. However, they do not show that rucaparib is overwhelmingly superior to rechallenge platinum. It points out that overall progression-free survival in both groups was disappointingly short, and the relative magnitude of benefit with rucaparib did not reach that reported for PARP inhibitors in early maintenance. It adds that large-scale testing for BRCA1/2 reversion mutations is feasible and probably predictive.